GenSight Biologics successfully raises €22.5 million from leading investors in the US and Europe

GenSight Biologics launches a capital increase of approximately €20 million

GenSight Biologics reports long-term positive safety and visual acuity results at Week 96 in Phase I/II Study of GS010 for the treatment of Leber’s Hereditary Optic Neuropathy (LHON)

GenSight Biologics to Present Data on GS010 and GS030 at the Annual Meeting of ARVO

GenSight Biologics Appoints Mohamed Genead as Chief Medical Officer

GenSight Biologics Announces the Filing of its 2016 Registration Document

GenSight Biologics to Present GS010 at the 4th Annual Retinal Cell & Gene Therapy Innovation Summit

GenSight Biologics to Present GS010 at the 2017 Annual Meeting of the American Academy of Neurology

GenSight Biologics to Attend Upcoming Investor Conferences

GenSight Biologics to Present Data on GS010 at the 43rd Annual Meeting of NANOS